Table 1.
Baseline characteristics of participants by treatment group (median, interquartile range)
| Variable | Placebo | 100 mg | 200 mg | 400 mg | P |
|---|---|---|---|---|---|
| No. of participants | 23 | 13 | 26 | 19 | |
| Age, y | 26 (24-33) | 35 (31-42) | 28 (24-32) | 31 (26-37) | .02a,b |
| Weight, kg | 85 (74.1-90.8) | 89.7 (78.8-102.4) | 81.4 (75.2-90.9) | 78.4 (67.5-87.6) | .13 |
| BMI, kg/m2 | 25 (23-27) | 30 (26-31) | 25 (23.3-27.8) | 25 (2328) | .05 |
| Serum T, ng/dL | 477 (415-571) | 390 (316-449) | 485 (366-565) | 492 (442581) | .08 |
| Serum E2, pg/mL | 20.8 (8.5-24.8) | 24.1 (14.1-25.4) | 18.5 (10.4-28.1) | 15.4 (12.521.1) | .75 |
| Serum CTX, ng/mL | 0.27 (0.19-0.32) | 0.16 (0.13-0.22) | 0.24 (0.18-0.3) | 0.18 (0.14-0.24) | .03a,c |
| Serum P1NP, ng/mL | 67.7 (54.5-82.9) | 54 (35.3-67.8) | 57.9 (44.6-68.9) | 64 (55.8-83.2) | .14 |
| Serum BAP, mcg/L | 6.9 (5.8-8.5) | 6.4 (5.9-6.7) | 6.6 (6.3-8.3) | 6.7 (5.6-7.3) | .44 |
P values of Kruskal-Wallis analysis of variance across groups.
Abbreviations: BAP, bone-specific alkaline phosphatase; BMI, body mass index; CTX, C-terminal telopeptide of type I collagen; E2, estradiol; P1NP, procollagen type I amino-terminal propeptide; T, testosterone.
a P less than .05 was significant.
b Significant pairwise comparisons were placebo vs 100 mg and 100 mg vs 200 mg.
c Significant pairwise comparison was 100 mg vs 200 mg.